Pre-existing IP is considered one of the risk factors for drug-induced pneumonitis caused by molecular-targeted therapy, especially by EGFR-TKIs, along with factors such as older age, smoking history, and poor performance status. This evidence concerns the gene EGFR and pneumonitis.